Chandigarh Herald

DelveInsight’s, “Diabetic Peripheral Neuropathy Pipeline Insights 2023,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Diabetic Peripheral Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Diabetic Peripheral Neuropathy pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, Diabetic Peripheral Neuropathy clinical trials studies, Diabetic Peripheral Neuropathy NDA approvals (if any), and product development activities comprising the technology, Diabetic Peripheral Neuropathy collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Key takeaways from Diabetic Peripheral Neuropathy Pipeline Report

• Diabetic Peripheral Neuropathy Pipeline report offers a comprehensive analysis of 20+ companies and 20+ therapies.

• The leading Diabetic Peripheral Neuropathy Companies included Lexicon Pharmaceuticals, Lateral Pharma Pty Ltd., SIMR (Australia) Biotech Pty Ltd., WinSanTor, Inc., Eli Lilly and Company, Daiichi Sankyo, Inc., Avazzia, Inc., and others.

• Promising Diabetic Peripheral Neuropathy pipeline therapies included such as CSPC ZhongQi Pharmaceutical Technology Co., Ltd, Helixmith, Aptinyx, Lexicon Pharmaceuticals, and others.

• The Diabetic Peripheral Neuropathy companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Peripheral Neuropathy R&D. The Diabetic Peripheral Neuropathy pipeline therapies under development are focused on novel approaches to treat/improve Diabetic Peripheral Neuropathy. 

To explore more information on the latest breakthroughs in the Diabetic Peripheral Neuropathy Pipeline treatment landscape of the report, click here @ Diabetic Peripheral Neuropathy Pipeline Outlook

Diabetic Peripheral Neuropathy Overview

Diabetic neuropathy is nerve damage caused by diabetes. When it affects the arms, hands, legs and feet, it is known as diabetic peripheral neuropathy. Diabetic peripheral neuropathy does not emerge overnight. Instead, it usually develops slowly and worsens over time. Some patients have this condition long before they are diagnosed with diabetes.

Recent Developmental Activities in the Diabetic Peripheral Neuropathy Treatment Landscape

• NYX-2925 is a novel, oral small molecule NMDA receptor modulator in development for the treatment of chronic pain. Dysregulation of glutamatergic circuits in the brain is involved in the development of centralized chronic pain. NYX-2925 is in late stage clinical development across two chronic pain indications -Painful Diabetic Peripheral Neuropathy and Fibromyalgia.

For further information, refer to the detailed Diabetic Peripheral Neuropathy Unmet Needs, Diabetic Peripheral Neuropathy Market Drivers, and Diabetic Peripheral Neuropathy Market Barriers, click here for Diabetic Peripheral Neuropathy Ongoing Clinical Trial Analysis

Diabetic Peripheral Neuropathy Emerging Drugs Profile

• FE-SYHA1402: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

ZhongQi Pharmaceutical Technology is conducting a multiple doses study to evaluate the safety, tolerability, pharmacokinetics (including food effect) of SYHA1402 in healthy subjects. This study consists of two parts: The objective of the food effect study (Part 1) is to investigate the effect of food on the pharmacokinetic profiles of SYHA1402 tablets under fed and fasted conditions following the oral administration of SYHA1402. The primary objective of the multiple doses study (Part 2) is to investigate safety, tolerability and Pharmacokinetics of SYHA1402 in healthy subjects following oral administration of Multiple rising doses. Secondary objectives are the exploration of pharmacokinetics (PK) following multiple oral doses.

• VM202: Helixmith

VM202 (donaperminogene seltoplasmid) is a first-in-class, proprietary, non-viral, potentially regenerative plasmid DNA gene therapy. VM202 is a novel genomic cDNA hybrid human hepatocyte growth factor (HGF) gene with a novel and proprietary coding sequence (HGF-X7) expressing two isoforms – a configuration that closely mimics HGF productions in humans that is needed for optimal therapeutic benefits. Because there is no change in the coding region of the HGF gene, HGF proteins generated from VM202 are identical to wildtype human HGF proteins.

• LX9211: Lexicon Pharmaceuticals

LX9211 is a potent, orally delivered, selective small molecule inhibitor of AAK1, a target discovered and extensively characterized in an alliance with Bristol Myers Squibb. Preclinical data demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain. Lexicon has exclusive research, development and commercialization rights to LX9211 and additional compounds acting through AAK1.

Diabetic Peripheral Neuropathy Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the therapies for Diabetic Peripheral Neuropathy. The companies which have their Diabetic Peripheral Neuropathy drug candidates in the most advanced stage, i.e. phase III include, Helixmith Co., Ltd. and Daiichi Sankyo.

Request a sample and discover the recent advances in Diabetic Peripheral Neuropathy Ongoing Clinical Trial Analysis and Medications, click here @ Diabetic Peripheral Neuropathy Treatment Landscape

Scope of the Diabetic Peripheral Neuropathy Pipeline Report

• Coverage- Global

• Diabetic Peripheral Neuropathy Companies- Lexicon Pharmaceuticals, Lateral Pharma Pty Ltd., SIMR (Australia) Biotech Pty Ltd., WinSanTor, Inc., Eli Lilly and Company, Daiichi Sankyo, Inc., Avazzia, Inc., and others.

• Diabetic Peripheral Neuropathy pipeline therapies- CSPC ZhongQi Pharmaceutical Technology Co., Ltd, Helixmith, Aptinyx, Lexicon Pharmaceuticals, and others.

• Diabetic Peripheral Neuropathy Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Diabetic Peripheral Neuropathy Market Drivers and Diabetic Peripheral Neuropathy Market Barriers, click here @ Diabetic Peripheral Neuropathy Unmet Needs and Analyst Views

Table of Content

1. Introduction
2. Executive Summary
3. Diabetic Peripheral Neuropathy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Diabetic Peripheral Neuropathy – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Diabetic Peripheral Neuropathy Collaboration Deals
9. Late Stage Products (Phase III)
10. Engensis: Helixmith Co., Ltd.
11. Mid Stage Products (Phase II)
12. Aptinyx: NYX-2925
13. LX9211: Lexicon Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. FE-SYHA1402: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
17. SR419: SIMR (Australia) Biotech Pty Ltd.
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Comparative Analysis
21. Diabetic Peripheral Neuropathy- Market Drivers and Barriers
22. Appendix

Got Queries? Find out the related information on Diabetic Peripheral Neuropathy Mergers and acquisitions, Diabetic Peripheral Neuropathy Licensing Activities @ Diabetic Peripheral Neuropathy Emerging Drugs, and Recent Trends

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/